Metastatic castration resistant prostate cancer: Updates from ASCO 2019
Dr Neal Shore, Dr Joaquin Mateo and Prof Karim Fizazi
Metastatic castration resistant prostate cancer: Updates from ASCO 2019 ( Dr Neal Shore, Dr Joaquin Mateo and Prof Karim Fizazi )
7 Jun 2019
Prostate cancer updates: TITAN and ENZAMET
Prof Ian Davis and Prof Axel Merseburger
Prostate cancer updates: TITAN and ENZAMET ( Prof Ian Davis and Prof Axel Merseburger )
3 Jun 2019
Clinical updates for metastatic hormone sensitive prostate cancer at ASCO 2019
Prof Rob Jones, Prof Nick James, Prof Ian Davis, Prof Axel Merseburger
Clinical updates for metastatic hormone sensitive prostate cancer at ASCO 2019 ( Prof Rob Jones, Prof Nick James, Prof Ian Davis, Prof Axel Merseburger )
3 Jun 2019
Metastatic bladder cancer: Current practice and latest data from ASCO 2019
Dr Andrea Necchi, Dr Petros Grivas, Prof Arlene Siefker-Radtke, Prof Rob Jones
Metastatic bladder cancer: Current practice and latest data from ASCO 2019 ( Dr Andrea Necchi, Dr Petros Grivas, Prof Arlene Siefker-Radtke, Prof Rob Jones )
3 Jun 2019
Highlights from ASCO 2019
Asst. Prof Bishal Gyawali and Monique Biryiana
Highlights from ASCO 2019 ( Asst. Prof Bishal Gyawali and Monique Biryiana )
3 Jun 2019
Targeting agent enfortumab vedotin a novel treatment for patients with advanced ...
Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA
Targeting agent enfortumab vedotin a novel treatment for patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )
3 Jun 2019
New agent targeting Nectin-4 produces responses in nearly half of patients with ...
Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA
New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )
3 Jun 2019
Novel therapies in the treatment of bladder cancer
Dr Petros Grivas and Dr Andrea Necchi
Novel therapies in the treatment of bladder cancer ( Dr Petros Grivas and Dr Andrea Necchi )
3 Jun 2019
Update on CARMENA trial: Cytoreductive nephrectomy in metastatic renal cancer wi...
Prof Arnaud Mejean - Paris Descartes University, Paris, France
Update on CARMENA trial: Cytoreductive nephrectomy in metastatic renal cancer with focus on intermediate IMDC-risk population ( Prof Arnaud Mejean - Paris Descartes University, Paris, France )
3 Jun 2019
Enzalutamide as treatment for men with mHSPC who have received testosterone supp...
Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA
Enzalutamide as treatment for men with mHSPC who have received testosterone suppression ( Dr Christopher Sweeney -  Dana-Farber Cancer Institute, Boston, USA )
2 Jun 2019
Enzalutamide improves survival for men with metastatic hormone-sensitive prostat...
Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA
Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer ( Dr Christopher Sweeney -  Dana-Farber Cancer Institute, Boston, USA )
2 Jun 2019
Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroi...
Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, USA
Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroids improving quality of life ( Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, USA )
2 Jun 2019